ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

DNA Doric Nimrod Air One Limited

60.00
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Doric Nimrod Air One Limited LSE:DNA London Ordinary Share GG00B4MF3899 ORD PRF SHS NPV
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 60.00 59.00 61.00 - 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Doric Nimrod Air One Share Discussion Threads

Showing 101 to 114 of 250 messages
Chat Pages: 10  9  8  7  6  5  4  3  2  1
DateSubjectAuthorDiscuss
21/2/2007
13:25
Genentech Lexicon Genetics posts 4Q loss of $13.8M


THE WOODLANDS, Texas (AP) - Biopharmaceutical company Lexicon Genetics Inc.
said Wednesday it swung to a loss in the fourth quarter, largely because the
comparable 2005 period benefited from unusually robust revenue.
The company posted a quarterly loss of $13.8 million, or 19 cents per share,
compared with a profit of $5.9 million, or 9 cents per share during the same
period in 2005. Revenue fell 53 percent to $16.1 million from $33.9 million.
Analysts polled by Thomson Financial forecast a loss of 24 cents per share
on revenue of $15.6 million.
The company said it faced tough comparisons with the same quarter of a year
ago, when Lexicon received $20 million in performance milestone payments from
its development partner Genentech Inc.
Excluding those payments, revenue increased on a year-over-year basis by 16
percent, the company said. It cited revenue from development partner Organon.
The company's annual loss widened to $54.3 million, or 81 cents per share,
from $36.3 million, or 57 cents per share in 2005. Revenue fell 4 percent to
$72.8 million from $75.7 million.

ariane
15/1/2007
20:12
Tanox shareholders approve 919 mln usd Genentech merger


HOUSTON (AFX) - Drug developer Tanox Inc said its shareholders have voted in
favour of accepting a 20 usd per share takeover offer made last November by
Genentech Inc, which values the company at 919 mln usd.
Around 34.2 mln shares were voted in favour of the merger agreement at a
shareholders' meeting, representing about 75.5 pct of Tanox's total shares and
99.9 pct of the shares voted at the meeting, it said.
The transaction is seen closing in the first quarter of 2007, it added.
newsdesk@afxnews.com
har

waldron
12/1/2007
12:10
Roche Ag Genentech, BioInvent agree to co-develop cardiovascular drug


ZURICH (AFX) - BioInvent AB said it has entered a deal with Genentech Inc --
majority owned by Roche -- to co-develop and commercialise BioInvent's
proprietary antibody candidate, BI-204, for the treatment of multiple
cardiovascular conditions.
BioInvent will receive an upfront 15 mln usd from Genentech, as well as
further potential milestone payments of up to 175 mln usd and royalties on sales
in North America, the Swedish biotech firm said.
Under the terms of the agreement, Genentech and BioInvent will be jointly
responsible for clinical development, with Genentech enjoying exclusive
commercialisation rights in North America and BioInvent having those for the
rest of the world.
afx.zurich@afxnews.com
jmt/abr

waldron
11/1/2007
06:30
Biotech group's profits up 75%
By Rebecca Knight in Boston

Published: January 11 2007 02:00 | Last updated: January 11 2007 02:00

Genentech yesterday said its fourth-quarter profits rose 75 per cent, driven by the successful introduction of its new eye-loss treatment and strong demand for its cancer drug.

The San Francisco-based company, which is the second-largest biotechnology company by sales after Amgen, said its net income increased to $594m, or 56 cents a share, from $339.2m, or 31 cents, a year earlier. Revenue rose 43 per cent to $2.71bn, beating analysts' average estimate of $2.5bn.

Geoffrey Meacham, JPMorgan's US biotechnology analyst, said in a brief note that, "as expected", Genentech posted "strong top andbottom-line performance" on the strength of two key drugs, Avastin and Lucentis.

Lucentis, which is co-marketed internationally with Novartis of Switzerland, is Genentech's newest drug, approved and launched last June.

US sales of Lucentis, a treatment for leaking blood vessels in the eye that can cause blindness, were $217m in the quarter, beating analysts' consensus estimates of $159m.

Mr Meacham raised his outlook for 2006, 2007 and 2008 sales of the drug.

US sales of Avastin, the colon cancer drug, rose 36 per cent to $490m. Avastin, the company's fastest-growing product since its approval in 2004, won US approval last October as a lung cancer treatment. The solid growth of Genentech's other cancer drugs - Rituxan and Herceptin - also helped boost performance.

In a research note, Steven Harr, an analyst at Morgan Stanley, said the results were strong across the board. "Most importantly, demand for Avastin, which is the major source of investor dispersion, grew . . . We expect the Street will like these numbers."

Arthur Levinson, chairman and chief executive officer, said he was pleased with the company's pipeline and that he planned to "continue to focus on R&D projects".

Shares of Genentech, majority-owned by Swiss drug-maker Roche Holding, dropped 97 cents to $83.72 yesterday but were up in after-hours trading. The company reported results after markets closed.

waldron
10/1/2007
08:16
US Supreme Court supports MedImmune's position in patent dispute with Genentech


ZURICH (AFX) - The US Supreme Court in Washington has ruled that US biotech company MedImmune Inc does not infringe a Genentech Inc production-patent known as Cabilly-II, thus enabling MedImmune to go ahead with its own related lawsuit against Genentech. MedImmune had previously disputed the patent, but had continued to pay royalties to Genentech, which is majority-owned by Swiss pharma group Roche Holding AG. The Cabilly patent is used by MedImmune to make Synagis, a drug that treats childhood respiratory problems. afx.zurich@afxnews.com at/ic

waldron
03/1/2007
09:56
Roche Ag Genentech, Exelixis sign cancer R&D agreement


ZURICH (AFX) - Genentech Inc, in which Roche Holding AG holds a majority
stake, said it reached a worldwide agreement with Exelixis Inc on the worldwide
co-development of XL518, an MEK-inhibitor used in the treatment of tumours.
Under the terms of the agreement, Exelixis will receive up-front and
milestone payments of around 40 mln usd.
Exilixis will be responsible for Phase I development of the inhibitor and
will receive further payments should Genentech decide to further pursue the
drug's development.
afx.zurich@afxnews.com
at/jlw

waldron
24/12/2006
11:26
America's 400 Best Big Companies
The Best Of The Best
Matthew Herper 01.08.07


Drugs & Biotechnology

Genentech

In the past three years $9 billion (sales) Genentech has launched three new drugs: the $2 billion (sales) cancer treatment, Avastin, Lucentis for macular degeneration ($400 million sales) and a pill, Tarceva, for lung cancer, with sales of $400 million. But the company's biggest success last year came from the breast cancer medicine Herceptin, an old drug for which Chief Executive Arthur Levinson helped lay the groundwork as a Genentech research scientist 26 years ago.

In early-stage breast cancer, Herceptin doubles a woman's chances of living cancer free. Those stunning results have nearly tripled the drug's annual sales to $1.3 billion and answer a challenge Levinson says was proffered by Andy Grove: Save lives, don't just extend them for a few months. Over the past five years Genentech's sales have grown at an annualized 33% and earnings at 95%. Genentech must deal with controversy over high drug prices--even with a new price cap Avastin can cost $55,000 a year. Can the company keep up its winning streak? Levinson is focusing on research into diseases where the immune system goes wrong, like rheumatoid arthritis, multiple sclerosis and allergies. Which explains Genentech's decision last November to buy asthma drug maker Tanox for $919 million in cash.

maywillow
13/11/2006
08:16
Genentech's MabThera improves rheumatoid arthritis with repeat treatment - trial

ZURICH (AFX) - Genentech Inc, in which Basel-based pharma group Roche
Holding AG holds a majority stake, announced positive data from new trials with
MabThera/Rituxan against rheumatoid arthritis (RA).
According to Genentech, the new data presented at the American college of
Rheumatology congress shows an improvement in the physical as well as mental
improvement in the quality of life of patients treated repeatedly with the drug.
RA is one of the most common auto-aggressive diseases, affecting around 21
million people worldwide.
afx.zurich@afxnews.com
at/jlw

ariane
10/11/2006
05:26
Genentech buys Tanox for $919 million

SAN FRANCISCO (AFX) - Genentech Inc. intends to acquire the tiny
biotechnology company Tanox Inc. for $919 million in cash, the South San
Francisco-based drug maker announced Thursday.
The acquisition will help streamline a three-way partnership the two
companies share with Novartis AG in the development and commercialization of the
asthma-fighting drug Xolair, which was created by Tanox. Once the deal is
completed, Genentech no longer will have to make royalty payments to Tanox while
receiving such payments from Novartis.
Genentech is offering $20 per share for Houston-based Tanox, a premium of 47
percent to that company's closing price of $13.64 on the Nasdaq Stock Market.
The stock has traded between $11.55 and $21 over the past 52 weeks.
In after hours trading, Genentech's stock fell 20 cents a share to $81.15.
Houston-based shares of Tanox rose $5.86, or 43 percent, to $19.50.

grupo guitarlumber
11/10/2006
15:29
Roche Benefits From Genentech Guidance

Wednesday, October 11, 2006 6:32:36 AM ET
Dow Jones Newswires



0917 GMT [Dow Jones]--Roche (RHHBY) will benefit from Genentech's (DNA) raised EPS guidance, says Kepler Equities. Genetech's 3Q earnings were higher than seen due to strength of Lucentis, even if other drugs were weaker than seen. "3Q results show the benefits of a broad pipeline," Kepler Equities says. Roche (RHHBY) continues to be a strong pick, analyst says, citing an expected boost in Avastin once it's approved for non-small cell lung cancer, which could come already Thursday. Shares +0.1% at CHF220.60. (HJS)

grupo guitarlumber
26/9/2006
07:45
Genentech warns cancer drug Avastin patients of rare brain condition link

WASHINGTON (AFX) - Genentech Inc, majority owned by Switzerland's Roche
Holding AG, has added warnings about a rare brain condition linked to its cancer
drug Avastin, the US Food and Drug Administration said on its website.
The new label warns patients using the drug about the possibility of
developing a rare brain condition, reversible posterior leukoencephalopathy
syndrome (RPLS), the FDA said.
But Genentech said Avastin studies had shown that less than 0.1 pct of
patients taking Avastin had shown RPLS symptoms.
The blockbuster's warnings and adverse reactions notice now also includes
information about seven reports of patients who developed holes inside the nose
called septum perforations, the FDA said.

afx.zurich@afxnews.com
jmt/vs

waldron
08/8/2006
12:47
Genentech, Genizon sign license agreement for Crohn's disease GeneMap

LONDON (AFX) - Genentech Inc has signed an agreement to license Genizon
BioSciences's GeneMap of disease-associated genes, generated from a recent study
of Crohn's disease patients in the genetically homogenous Quebec Founder
Population, the two companies said.
The GeneMap will be used to develop new therapeutic products for Crohn's
disease.
Financial details of the deal were not disclosed.
newsdesk@afxnews.com
har

grupo guitarlumber
27/6/2006
07:18
Roche declines comment on financial impact of Avastin trial failure

BASEL (AFX) - Roche Holdings AG declined to comment on the financial impact
of today's abandonment of Phase III clinical trials of Avastin as a first-line
treatment for advanced pancreatic cancer.
"We don't want to speculate," a spokesman for the Swiss pharma group said.
However, pancreatic cancer is a not very common form of the disease compared
with colorectal, lung and breast cancer, he noted.
Avastin -- jointly developed with Genentech Inc, in which Roche holds a
majority stake -- is already approved in the US and Europe for first-line
treatment of patients with advanced colorectal cancer.
Avastin was filed in the US in April for the most common form of lung cancer
and in Japan, also in April, for treatment of advanced colorectal cancer.
Most recently, the drug was filed in the US for the treatment of advanced
breast cancer.
Roche last year recorded Avastin sales of 1.665 bln sfr.
afx.zurich@afxnews.com
at/vs

ariane
13/6/2006
07:26
Alzheimer's vaccine 'promising'

The vaccine was tested on mice
A potential DNA vaccine for Alzheimer's disease has produced promising results in mice.
In tests it helped cut levels of key amyloid proteins thought to cause the disease by up to 50% in some parts of the brain.

And unlike alternative vaccines in development, which use viruses, it produced no side effects.

The Japanese study appears in the journal Proceedings of the National Academy of Sciences.

This work represents a promising new line of vaccine development

Dr Clive Holmes

Over-production of amyloid proteins are thought to trigger symptoms of Alzheimer's by forming clumps that litter the brain.

Previous studies have shown that it is possible to stimulate the immune system of mice to attack these plaques if they are immunised with amyloid protein.

This approach has been tested in preliminary trials on humans, but early results showed that the immune response was too strong, leading to damaging swelling of the brain, as well as plaque destruction.

New studies in man are currently underway that hope to mobilise the immune response in a less aggressive manner so that plaques are destroyed, but brain swelling is avoided.

Gentle response

The latest approach, developed by a team at Tokyo Metropolitan Institute for Neuroscience, works by stimulating the body to produce small amounts of amyloid protein itself.

Mice are injected with naked DNA that codes for these proteins, rather than relying on a special virus to get it into the cell.

This has the effect of producing a more gentle immune response, and importantly the DNA has also been designed so that it is not capable of replicating itself by incorporating itself into the human genome.

In tests, the latest vaccine reduced the deposition of amyloid proteins by between 15.5% and 38.5% compared with untreated mice.

Deposition in specific areas of the brain - the cerebral cortex and hippocampus - was reduced 40%-50%.

The researchers suggest that DNA vaccines of the type they have produced could provide a cheap and effective strategy for treating Alzheimer's in future.

Dr Clive Holmes, of the Alzheimer's Research Trust, said the Toyko study held great promise.

He said: "This work represents a promising new line of vaccine development but more research would be needed to see if this could be replicated safely in humans."

Dr Susanne Sorensen, of the Alzheimer's Society, agreed that the fact that the vaccine appeared safe was significant.

She said: "The findings support the idea that a vaccine is our best hope for fighting this devastating disease for which there is currently no cure."

grupo guitarlumber
Chat Pages: 10  9  8  7  6  5  4  3  2  1

Your Recent History

Delayed Upgrade Clock